Our Senior Scientist, Kawanobe Ph.D., the first author, published in Nucleic Acid Therapeutics collaborative research with Axcelead Drug Discovery Partners, Inc. using XNAs technology. 2025/03/27 Notice Read
Notice of Conclusion of License Agreement with Summit Pharmaceuticals International Corporation for the Manufacture and Sale of Artificial Modified Nucleic Acid Amidite 2024/12/17 Notice Read
Result of the Ex-post evaluation of the Spinal Cord Injury (SCI) Program of Cyclic Innovation for Clinical Empowerment (CiCLE) supported by Japan Agency for Medical Research and Development (AMED) 2024/11/28 Notice Read
We have been selected for the “Research and Development Program for Innovative Biologics” in 2024. 2024/09/12 Notice Read
Notice of a collaboration agreement with Renascience, Inc. to develop antisense oligonucleotides for treating hereditary neurological intractable diseases 2024/06/24 Notice Read
Notice：Luxna Biotech and Head Office for Open Innovation Business Development Strategy, Tohoku University Announce the Initiation of the Collaborative Research for Creation of Antisense Oligonucleotide for the Treatment of Hearing Loss 2023/12/22 Notice Read
